Clinical study: AB-Gen

Randomized clinical trial, double-blind, controlled, naturalistic, multicenter and prospective, enrolling 316 patients with severe depressive disorder: 

  • Currently it is the largest randomized clinical trial (RCT), using a pharmacogenetic test in patients
  • Intended to evaluate the effectiveness of Neurofarmagen in the choice of pharmacological treatment, with improvement measured by the Patient Global Impression of Improvement (PGI-I) scale within 12 weeks.